Albrecht Stenzinger
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (30)
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Year:
2025
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2025
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Year:
2025
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Year:
2025
Supplementary Figure 1. (Top) Venn Diagram showing the intersect between Hypoxia-M V2 significant DMPs (n=3397) and Hypoxia-M V1 significant DMPs (n=5129) 2551 (66%) of significant DMPs identified based on the 85th percentile of standard deviation are also included in the selection criteria of Hypoxia-M V1. (middle) Hypoxia-M V2 is prognostic in the TCGA HNSCC cohort (p=0.041) and the prognostic effect remained independent on multivariate analysis. (bottom) Multivariate Analysis revealed that patients predicted to have high Hypoxia by Hypoxia-M V2 had worsened OS outcomes (HR=1.59, p
Year:
2025
Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p
Year:
2025
Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort. Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death (p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.027) and disease progression (p=0.00096). (Bottom) Hypoxia-M V2 remains an independent prognosticator of OS, LR and disease progression after adjusting for age, smoking status, GTV and anatomical site. Additionally, there is a trend towards higher rates of distant metastasis (HR=2.33, p=0.13)
Year:
2025
Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS), local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) After adjusting for Immune cell Infiltration, Hypoxia-M remained an independent prognosticator for local recurrence (HR=3.06, p
Year:
2025
Desmoplastic small round cell tumor (DSRCT) is an ultra-rare sarcoma with limited treatment options. We performed whole-genome/exome, transcriptome, and DNA methylome analysis in 30 refractory DSRCT patients, complemented by (phospho)proteomic profiling in nine, within a nationwide precision oncology program. In eight patients (27%), DSRCT was diagnosed based on molecular profiling. Although all patients had “quiet” genomes, 28 (93%) received 107 molecular-based management recommendations, including assessment of clinical trial eligibility in 17 (57%). Nearly half of recommendations (45%) were based on overexpression of tyrosine kinases, as well as SSTR3/5 and CLDN6, detected in 33% and 20% of cases, respectively. Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%; partial response, n = 5; stable disease, n = 3), including three long-lasting responses (≥ 12 months) to pazopanib and trastuzumab deruxtecan, triggered by ERBB2 overexpression in the absence of constitutive ERBB2 signaling. Thus, multi-omics profiling enables individualized DSRCT treatment.
Year:
2025
The ability to establish organoids composed exclusively of tumour rather than healthy cells is essential for their implementation into clinical practice. Organoids have recently emerged as a powerful tool to expand patient material in culture and generate modifiable 3D models derived from humans or animal models. For translational research, they enable the creation of model systems for an ever‐increasing number of cell types and diseases. And in personalised medicine, they potentially allow for functional drug testing with high predictive power in certain settings. We found that using biopsy material from untreated, early‐stage primary breast cancer patients poses significant challenges for consistently culturing tumour cells as organoids. Specifically, we observed frequent outgrowth of genetically normal, non‐cancerous epithelial cells. We analysed >100 biopsy samples from early‐stage breast cancer and present our large collection of >70 organoid lines. We also show methods of assessing successful tumour cell culture in a time, and cost‐efficient manner, proving a high rate (>85%) of normal cell overgrowth in early‐stage breast cancer organoids. Finally, we show a number of successful attempts to culture cancer organoids from mastectomy‐derived tissue of advanced, metastatic breast cancer. We conclude that the usefulness of organoids from early breast cancer for translational research and personalised medicine, especially guidance of adjuvant or post‐surgical maintenance therapy, is strongly limited by the low success rate of culturing cancerous cells under organoid conditions.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (52)
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Neal Akhave
Assistant Professor
The University of Texas MD Anderson Cancer Center
Christine Bestvina
Assistant Professor
University of Chicago Medicine
Sandip Patel
Associate Professor
Moores Cancer Center, UC San Diego Health
Marina Garassino
Prof
Università degli Studi di Torino
Richard F Schlenk
Head of trials office
Ruprecht Karls Universität Heidelberg
Frederick Klauschen
Professor, Chair
Ludwig-Maximilians-Universität München
Jacobi Hines
Assistant Professor
Northwestern Medicine
Bernhard Kuster
Technical University of Munich
Qi Wang
The University of Texas MD Anderson Cancer Center
Mizuki Nishino
King’s College London
Petros Christopoulos
-
Panagiotis Balermpas
University Hospital of Zurich
Daniel Hübschmann
Research Group Leader
Deutsches Krebsforschungszentrum
Amy L Cummings
UCLA School of Medicine
Soni Savai Pullamsetti
Max Planck Institute for Heart and Lung Research
Giorgio V Scagliotti
Chair
University of Turin
james hicks
H Lee Moffitt Cancer Center and Research Institute
Mingjia Li
Assistant Professor
Ohio State University
Matthew The
Technical University of Munich
Wolfgang Hartmann
MD, Consultant, Professor for Molecular Pathology
University Hospital Münster
Thorsten Stiewe
Director
Philipps-Universität Marburg
Cihan Erkut
Senior Scientist
Deutsches Krebsforschungszentrum
Collin Blakely
Assistant Professor
UCSF Medical Center
Peter Horak
Deputy Head of Department
UniversitätsKlinikum Heidelberg
Matthias Scheffler
University Hospital Bonn
John V. Heymach
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Heather Wakelee
Professor
Stanford University
Christel Herold-Mende
University Hospital Heidelberg
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Matthias Schlesner
University of Augsburg
Xiang Zheng
Group Leader
Aarhus University
Hauke Winter
Department Head / Prof. Dr. med
Heidelberg University
Ying Ni
Assistant Professor
Case Western Reserve University
Catherine Shu
Columbia University Irving Medical Center
Sebastian Bauer
Professor / Chair
Universität Duisburg-Essen
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
Mechthild Krause
Director
University Hospital Essen
Ingeborg Tinhofer-Keilholz
Charité - Universitätsmedizin Berlin
Juliane Hörner-Rieber
Chair
Heinrich Heine University Düsseldorf
Andreas Weigert
Full Professor
Goethe University Frankfurt
Marcelo Negrao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Martin Sprick
Heidelberg University
Dwight H. Owen
Ohio State University
Stephanie Elisabeth Combs
Professor and Chair
Technical University of Munich (TUM)
Daniel Zips
Chair, Professor, Director
Charité - Universitätsmedizin Berlin
Steffen Löck
-
Make your next move.
Prepare your application
Review drafts before you send them.